.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,004,297

« Back to Dashboard
Patent 6,004,297 protects LEVEMIR FLEXPEN, VICTOZA, NORDITROPIN NORDIFLEX, NOVOLOG MIX 70/30 FLEXPEN, and NOVOLOG FLEXPEN, and is included in five NDAs.

Protection for NOVOLOG FLEXPEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-six patent family members in twenty-one countries.

Summary for Patent: 6,004,297

Title: Injection syringe
Abstract:An injection syringe comprises a housing (1), a piston rod (6) with a non-circular cross-section and an outer thread (7), a piston rod drive which includes a piston rod guide (85) mating with the cross-section of the piston rod (6), and a nut (4) which is not axially displaceable and which mates with the thread (7) of the piston rod (6) to form a self-locking thread connection. Rotation of a dose setting element (81) causes an injection button to be screwed out to project from the housing (1). When the injection button (88) is pushed axially, such axial movement is transformed, by way of the threaded coupling, into a rotation of one of the piston drive elements (85) relative to the other one (4). A unidirectional coupling between the nut member (4) and the piston rod guide (85) allows rotation in one direction by which the piston rod (6) is transported in a distal direction. The coupling has an initial reluctance to be overcome before rotation takes place, said reluctance being large enough to resist torques exerted during the dose setting.
Inventor(s): Steenfeldt-Jensen; S.o slashed.ren (Hornb.ae butted.k, DK), Hansen; Steffen (Hiller.o slashed.d, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:09/238,849
Patent Claim Types:
see list of patent claims
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 9th percentile
Forward Citations: 3rd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
LEVEMIR FLEXPEN
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-002Jun 16, 2005DISCNNo6,004,297► subscribeY
Novo Nordisk Inc
VICTOZA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYes6,004,297► subscribeY
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-004Oct 1, 2004DISCNNo6,004,297► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,004,297

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark00130/98Jan 30, 1998

Non-Orange Book Patents for Patent: 6,004,297

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE43834Injection syringe► subscribe
6,235,004 Injection syringe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,004,297

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria197408► subscribe
Australia2265099► subscribe
Australia748277► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc